Therapeutic Effect of Anti-CD52 Monoclonal Antibody in Multiple Sclerosis and Its Animal Models Is Mediated via T Regulatory Cells.
Journal
Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
received:
22
02
2021
accepted:
27
04
2022
pubmed:
25
6
2022
medline:
2
7
2022
entrez:
24
6
2022
Statut:
ppublish
Résumé
The objective of this study is to determine the mechanism of action of anti-CD52 mAb treatment in patients with relapsing-remitting multiple sclerosis (RRMS). Experimental autoimmune encephalomyelitis (EAE), an animal model of the disease, was used to address the role of T regulatory cells (Tregs) in the anti-CD52 mAb-induced suppression of the disease. In vitro studies on PBMCs from RRMS patients and matched healthy controls determined the effect of IL-7 on the expansion of CD4
Identifiants
pubmed: 35750335
pii: jimmunol.2100176
doi: 10.4049/jimmunol.2100176
pmc: PMC9458467
mid: NIHMS1803119
doi:
Substances chimiques
Forkhead Transcription Factors
0
Interleukin-17
0
Alemtuzumab
3A189DH42V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
49-56Subventions
Organisme : NIAID NIH HHS
ID : R01 AI123193
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI131238
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI160774
Pays : United States
Organisme : NIAID NIH HHS
ID : R03 AI111592
Pays : United States
Informations de copyright
Copyright © 2022 by The American Association of Immunologists, Inc.
Références
Lancet. 2012 Nov 24;380(9856):1819-28
pubmed: 23122652
J Clin Cell Immunol. 2013 Jul 8;4(4):
pubmed: 24363961
Immunity. 2002 Aug;17(2):211-20
pubmed: 12196292
Immunology. 2012 Feb;135(2):168-79
pubmed: 22044096
Br J Haematol. 2006 Nov;135(4):475-85
pubmed: 16995884
Methods Mol Biol. 2011;707:157-72
pubmed: 21287334
N Engl J Med. 2008 Oct 23;359(17):1786-801
pubmed: 18946064
Sci Transl Med. 2011 Jul 27;3(93):93ra68
pubmed: 21795588
Immunology. 2009 Oct;128(2):260-70
pubmed: 19740383
Nat Immunol. 2007 Feb;8(2):191-7
pubmed: 17136045
Neurology. 2012 Apr 3;78(14):1069-78
pubmed: 22442431
J Immunol Methods. 2014 Apr;406:58-65
pubmed: 24642426
J Immunol. 2005 Feb 15;174(4):1783-6
pubmed: 15699103
J Immunol. 2006 Oct 15;177(8):5290-5
pubmed: 17015714
J Immunol. 2013 Dec 15;191(12):5867-74
pubmed: 24198283
J Neurol Sci. 2003 Feb 15;206(2):165-71
pubmed: 12559505
Expert Rev Neurother. 2012 Mar;12(3):335-41
pubmed: 22364332
Clin Immunol. 2018 Dec;197:45-53
pubmed: 30149119
Acta Neuropathol Commun. 2014 Dec 05;2:163
pubmed: 25476447
J Immunol. 2019 Sep 1;203(5):1142-1150
pubmed: 31341075
Eur J Immunol. 2005 Nov;35(11):3332-42
pubmed: 16231285
J Immunol. 2009 Dec 1;183(11):7602-10
pubmed: 19917691
Life Sci. 2016 May 1;152:244-8
pubmed: 26596563
J Neuroimmunol. 2017 Feb 15;303:22-30
pubmed: 28087077
Immunology. 2014 Jan;141(1):123-31
pubmed: 24116901
Nat Immunol. 2009 Apr;10(4):385-93
pubmed: 19252490
J Neuroinflammation. 2018 Aug 11;15(1):225
pubmed: 30098594
Front Immunol. 2020 Oct 09;11:588682
pubmed: 33163004
J Immunol. 2012 Dec 1;189(11):5223-9
pubmed: 23089398
PLoS One. 2014 Jan 23;9(1):e86762
pubmed: 24466225
Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e194
pubmed: 26819963
J Exp Med. 2004 Apr 5;199(7):971-9
pubmed: 15067033
J Immunol. 2005 Jun 1;174(11):6571-6
pubmed: 15905493
J Neuroimmunol. 2015 Aug 15;285:4-12
pubmed: 26198912
Immunology. 2008 Jan;123(1):79-89
pubmed: 17897326